ROTTERDAM, the Netherlands, Feb 19 (Bernama-GLOBE NEWSWIRE) —Centrient Pharmaceuticals (“Centrient”), the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active pharmaceutical ingredient (API) amoxicillin trihydrate. In addition, the Delhi High Court also found Sinopharm Weiqida prima facie guilty of contempt of Court for illegally importing amoxicillin active ingredients in contravention of the previously granted preliminary injunction in place in India since April 2017. The Court further found that Sinopharm Weiqida has infringed the patent of Centrient.
Centrient, and its wholly owned subsidiaries, Centrient Pharmaceuticals Netherlands B.V. and Centrient Pharmaceuticals India Pvt. Ltd., announced today that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceutical Co., LTD (“Weiqida“) blocking the export, importation and sale of its amoxicillin active ingredient into India. The injunction prevents the importation of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India in any form.
No comments:
Post a Comment